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Sreeave Sixty previously untreated patients with high grade non-Hodgkimns lymphomas stages II-IV
received cyclophosphamide 750mgm2 i.v., doxorubicin 50mgm2 i.v., and vincristine 2mg i.v. on day 1,
prednisolone 100mg p.o. on days 1-5 and etoposide lOOmgm2 i.v. on days 3-5 (CHOP-VP16). After four
courses an involved field irradiation with a total dose of 25Gy was employed and followed by two additional
courses of CHOP-VP16. The overall response rate was 93%. with 49 patients (82%) achieving a complete
remission (CR). Seven patients had a partial response and four patients showed no response. During a
median follow-up period of 55 months, 22 of the 49 patients with CR relapsed, seven of them achieving a
second complete remission with the same drug regimen. A maintained complete remission of up to 68 months
was seen in 55% of all patients initially achieving CR. The median survival is 43 months. Mean side-effects of
this drug regimen were alopecia (89%), nausea/vomiting (76%) and leukopenia (61%). No therapy-related
deaths were seen. The results of this study demonstrate that this combined modality treatment produces high
complete remission rates and that more than half of these patients achieve long-term disease-free survival.
One of the major objectives of most current therapeutic
trials in high grade non-Hodgkin's lymphomas (NHL) is to
devise a form of treatment that will consistently induce a
high frequency of complete remissions and ultimately benefit
more patients in terms of longer disease-free survival. With
CHOP, the standard protocol of the past decade introduced
by McKelvey et al. (1976), complete remissions can be
obtained in 50-60% of all patients with high grade NHL.
Approximately half of these patients will eventually relapse
with a poor prognosis. Recent results of studies applying a
response-adapted chemotherapy (Fisher et al., 1984) or an
intensive chemotherapy with an alternating regimen
(Brittinger et al., 1986; Cabamilas et al., 1983; Canellos et
al., 1981; Hoppe, 1985; Laurence et al., 1982; Todd et al.,
1986) have shown higher complete remission rates which
seem to be more stable. Due to the complexity of these
protocols they have not been used extensively. In 1982 we
initiated a multicentre phase II trial with an easily applicable
protocol using the initial CHOP plus VP16 which has been
shown to be an effective single agent in NHL (Aisner et al.,
1982; Jones et al., 1972). Additionally patients received an
involved field irradiation. The results of this study are
presented here.
Tabl I Patients' data
Age
Sex
Karnofsky
Stage
B-symptoms
>50
.50
Male
Female
>80%
.80%
II
III
IV
Histology Centroblastic NHL
Immunoblastic NHL
Lymphoblastic NHL
Miscellaneous NHL
Miscellaneous NHL
3 Kil-ML (1 T-type, 2 B-type)
3 undifferentiated ML
I histiocytic ML
Patients and methods
Patients
Sixty previously untreated patients with high grade NHL
stages II-IV entered the study. Patient eligibility included:
histologically confirmed high grade NHL (Kiel classification
(Lennert et al., 1978)); no prior chemotherapy; no other
malignancy; stages II-IV (Ann Arbor classification). Patients
with lymphoblastic NHL aged <25 years were excluded
from this study.
Patients' data in terms of age, sex, Karnofsky index, stage
and histological subtype are shown in Table I. Median age
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Table n Incidence of extranodal
outcome
involvement and clinical
Localisation n Alive Death
Bone marrow 7 4 3
Liver 7 - 7
Pleura 5 1 4
Lung 4 1 3
Bone 4 1 3
Tonsil 4 4
Nose orbit 3 1
GI tract 3 2
Skin 3 1 -
Pericardium 3 3
Ovary uterus 2 -
Muscle 1
Kidney 1 1
Pancreas 1
n
39
21
30
30
48
12
20
17
23
20
17
23
13
7
65
35
50
50
80
20
33
28
39
33
28
38
22
12
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was 56 years (range 15-73 years). Three patients were under
30 years of age, 65% were over 50 and 40% over 60 years.
The details of extranodal involvement are summarised in
Table II.
Histological classification
Lymph node material after diagnosis of high grade NHL by
local pathologists was reviewed by Dr Karl Lennert or his
associates at the University of Kiel, Institute of Pathology,
and classified according to the criteria of Kiel classification
(Lennert et al., 1978). Immunophenotyping was performed
whenever possible and only the University of Kiel opinion
on histology was accepted.
Staging procedures
All patients underwent the following staging procedures:
chest X-ray p.a. and lateral; bone-scan; abdominal CAT-scan
and/or sonography; bilateral bone marrow biopsies of the
posterior iliac crest; lumbar puncture in patients with
lymphoblastic NHL; biochemical tests: AST, ALT, LDH,
alkaline phosphatase, bilirubine, creatinine, potassium,
sodium, calcium, CBC and platelet count.
Chemotherapy
Patients were treated with six courses of the following
regimen: cyclophosphamide 750mg m2 i.v., doxorubicin
50 mgm2 i.v. and vincristine 2mg i.v. on day 1,
prednisolone 100mg p.o. on days 1-5, etoposide OOmgm-2
i.v. on days 3-5. Between courses 4 and 5 an involved field
irradiation with a dose of 25Gy was employed. The regi-
men was administered every 21 days. If cytopenia
(WBC<3,000mm-3 or platelet count of <100,000mm-3)
was present on day 21, therapy was delayed for a maximum
of one week. A dose-adjusted course was given then. Patients
with lymphoblastic NHL received an intrathekal CNS-
prophylaxis with 15 mg methotrexate on days I and 5 in
courses 1 and 2 and additional brain irradiation with 25Gy
after course 4.
Radiotherapy
Twenty-one days after course 4 all patients in CR or PR
received an involved field irradiation with a total dosage of
25Gy in 10-12 single fractions. Patients with persisting
extranodal involvement were excluded. Irradiation was given
to all nodal involvements and gastrointestinal lesions.
Patients with lymphoblastic NHL received prophylactic CNS
irradiation with 25Gy after course 4. In patients with
meningeal involvement CNS irradiation was given during
course 1.
Evaluation of response
A complete restaging was performed after course 4, after
involved field irradiation and after course 6. Complete
remission (CR) required that all clinically, imaging or biopsy
detectable tumours had disappeared. Partial response (PR)
was defined as a reduction of >.50% in all measurable
tumours and the absence of new lesions. No response was
defined as less than 50% reduction of measurable lesions, no
change or progress of the disease.
Statistical analyses
Survival curves were calculated and plotted by the actuarial
method of Kaplan & Meier (1958). The significance of
difference in survival of subgroups, taking into account the
prognostic factors stage at diagnosis, histological subtype
and age, was analysed by the stratified version of the log
rank test (Peto et al., 1977).
Results
Between March 1982 and December 1985, 60 patients
entered the protocol. All of them were evaluated before
100-
: 50-
.0 o j
O..
1-
i
1 2 3
Time (years)
4 5 6
Fuwe 1 Overall survival ( ) including all causes of death
and event-free survival (-- -), event defined as death or relapse,
of the 60 patients.
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Figwe 2 Overall survival for subgroups of the 60 patients
according to histological subtype (Kiel classification). The advan-
tage in survival for centroblastic (-----,n=17), lymphoblastic
(---,n=13) and miscellaneous (..... n =7) as compared to
immunoblastic lymphomas ( , n =23) was statistically signi-
ficant (P<0.002).
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Figwe 3 Overall survival for the 60 patients using Ann Arbor
stage. The advantage in survival for stages II (---,n=20) and
III (....,n=17) as compared to stage IV ( .n=23) was
statistically significant (P< 0.0068).
treatment and judged acceptable on the basis of the criteria
outlined above. A complete remission was achieved in 49
patients (82%). Seven patients had a partial response and
four patients had no response.
Of the patients who achieved CR, 75% did so after four
courses of chemotherapy, the remaining achieved CR after
radiotherapy. No additional CR was seen after courses 5 and
6. During the follow-up period (24-69 months, median 55
months) 20 patients with CR relapsed after 1-16 months.
Two additional patients had a late relapse after 20 and 33
months respectively. In 20 patients the fifth and/or sixth
chemotherapy cycle was omitted or dose-adjusted due to
severe neutropenia after radiotherapy. Twelve of the patients
in this subgroup are still well and in CR. Eight patients
experienced a relapse and died. With a median follow-up of
55 months (24-69 months) the overall survival shows a
plateau at almost 50%, as illustrated in Figure 1. Only four
patients died after more than 16 months of observation (24,
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29, 30, 43 months) and one relapse occurred at 33 months
but the patient is still alive and in a stable second remission.
Twenty-nine patients died. The histological subtype of
immunoblastic lymphoma and stage IV are parameters
correlated with a poor outcome (Figures 2 and 3). The
presence of extranodal involvement (Table II) was an
unfavourable indication and the group of 29 patients who
died included 20 such patients. As can be seen in Table II,
involvement of the liver, lung, pleura, or bone indicates an
extremely poor prognosis. The presence of bone marrow
involvement does not seem to be as unfavourable as had
been expected. Disease progression and partial response (11
patients) were associated with extremely poor prognosis, all
patients dying within 12 months. Four patients were
recorded as suffering intercurrent death, since examination
before death had shown no evidence of disease. The causes
of death were: one pulmonary embolism, one myocardial
infarction, one perforating gastric ulcer, one stroke.
As indicated above, factors influencing overall survival,
CR rates and CR stability were histological subtype and
stage at diagnosis. All patients with miscellaneous or centro-
blastic lymphoma went into CR, whereas only eight of the
13 (61%) with lymphoblastic and 17 of the 23 (74%) with
immunoblastic lymphoma achieved CR. The influence of
these factors on survival is demonstrated in Figures 1 and 3.
With regard to centroblastic lymphoma, the probability of
survival at 60 months is 70% versus 25% for immunoblastic
Table III Toxicity of the protocol
WHO grade
1 2 3 4
Leukopenia 10 26 25 5
Thrombopenia - 11 5 2
Alopecia - 14 81
Nausea vomiting 32 30 15
Infection 4 18 10
Neurotoxicity 19 10 2
Stomatitis 10 16 2
Diarrhoea 22 2 2
Fever 16 8
Numbers representing percentage of patients suffering from the
given toxicity in at least one course of therapy (patients n=60).
lymphoma, the miscellaneous and lymphoblastic lymphoma
being intermediate with 53% and 59% respectively (Figure
2). The disadvantage in survival of immunoblastic lymphoma
was statistically highly significant (P<0.002, stratified log
rank test). As far as the stage of disease is concerned (Figure
3), stages II and III show comparable probable 5-year
survival rates of 61% and 58% respectively versus 29% for
stage IV. The advantage in survival of stages II and III
compared to stage IV was statistically highly significant
(P<0.0068, stratified log rank test). Age was not a signifi-
cant factor for survival in this study. For the discnrmination
age 50 the P value was 0.31 for an advantage in survival
for patients <50 years.
The toxicity of this combined modality treatment was
tolerable. Major side effects were alopecia, nausea/vomiting
and neutropenia. The incidence and severity of side effects
are shown in Table III. Severe and lasting cytopemna was
only seen in courses 5 and 6. In nine patients these courses
had to be omitted, and in 11 additional patients dose
adjustments became necessary. This group of patients did
not differ in terms of either CR rate or survival from
patients receiving the complete number of courses.
Discus
Long-term disease-free remissions are the major goal of
treatment in patients with high malignant NHL, as the past
decade has shown that the potential for cure exists in
subgroups of these patients. While the CHOP protocol
induced about 30% long-term remissions, recent studies
using response-adapted regimens or alternating regimens
with early use of a large number of effective antineoplastic
drugs have induced higher remission rates. First data indi-
cate a high stability of these remissions. These studies are
summarised in Table IV. CR rates vary from 73 to 95%.
Survival rates are either not given or the follow-up period is
short: the 2-year survival in these studies is approximately
70%. Only Klimo et al. (1985) report a higher survival rate
of 76% with a follow-up of 28-40 months. Studies by
Cabanillas et al. (1983) also found a higher incidence of CR
and a higher probability of survival. All these studies,
however, either give results about subgroups (stages I-III.
Table IV Review of literature
Protocol
COPLAM
M-BACOD
Pro-MACE-MOPP
ACOMLA
CHOPRHOAP VIM
MACOP-B
ProMACE-Cyta-BOM
Multidrug
Alternating
Multidrug
Alternating
CHOP-VP16
n CR (%)
33 73
Plateau of
overall
survival (%)
68
Median
follow-up
months
24
42 78
74 74 70 24
24 75
56 82'
61C 84
28 89
97d 87
50 st. IV
90 St. 1-111
76
60b
45c
44 95
60 82
24
28-40
24
26
55
Remarks
DH
St. III-IV
DH, DU
st. III-IV
diffuse L
St. II-IV
DH
33% relapse
DLC, DU
St. I-IV
DLC
st. II-IV
diffuse L
st. II-IV
diffuse L
follic. 1-cell
st. I-IV
lymphobl. L
St. I-IV
high grade
Kiel class.
St. II-IV
Author
Laurence et al.
Canellos et al.
Fisher et al., 1983
Todd et al.
Cabanillas et al.
Klimo et al.
Fisher et al., 1984
Coiffier et al.
Coleman et al.
Present study
"Stage IV 66%, stages 1-111 100%; bevaluated at plateau; '72% intermediate grade; dintermediate grade; csubgroup of high-grade ML
evaluated at plateau; DH, diffuse histiocytic, mainly corresponding to centroblastic L according to Kiel classification; DU, diffuse
undifferentiated; DLC, diffuse large cell, centroblastic and low-grade according to Kiel classification; diff. L, all diffuse lymphoma.82 H. KOPPLER et al.
Cabamilas) or include patients with intermediate-grade NHL
(Working Formulation) which corresponds to low grade
NHL or in part to centroblastic lymphoma of the Kiel
Classification (Lennert et al., 1978; non-Hodgkin's Lym-
phoma Pathologic Classification Project, 1982). Klimo et al.
(1985) and Coiffier et al. (1986) reached a plateau of overall
survival at 76% and 45% of the total patient group respec-
tively. A major disadvantage of these regimens is high
toxicity and complexity of the treatment.
Another approach towards intensifying therapy has been
the combination of chemotherapy and radiotherapy (Hoppe,
1985; Klimo et al., 1985). O'Connell et al. (1986) reported a
62% 4-year survival rate in patients treated with eight
courses of COPA (similar to CHOP) and additional radio-
therapy. The results were clearly superior to those of
Coltman et al. (1986) with chemotherapy (COPA) alone.
O'Connell et al. (1984), however, in a randomised study of
adjuvant radiotherapy in advanced NHL found an advan-
tage in stage III only, while patients with stage IV did not
benefit.
We report the results of a combined modality treatment
with CHOP supplemented with etoposide and an involved
field irradiation with 25Gy. CR rate (82%), overall survival
(50% at 60 months), and disease-free survival are com-
parable to data ascertained using more aggressive methods
of treatment. The data presented are compared with those
reported by other authors for the treatment of histological
subgroups which correspond to high grade NHL according
to the Kiel classification. Coleman et al. (1986) included
young patients (80% <40 years) with lymphoblastic ML only
and found a high CR rate (95%) with a probability of
survival plateauing at 46%. They found a clear influence of
stage and risk factors on survival rate. The study of Coiffier
et al. (1986) shows comparable results for the high grade ML
(CR rate 84% and a probability of overall survival of 46%
at plateau phase).
Toxicity of our protocol was mild and treatment-limiting
in courses 5 and 6 only. No therapy-related deaths occurred.
Of the 22 patients in CR who relapsed nine did so within
previously irradiated areas only, suggesting that the dosage
of 25 Gy may not be suflicient and needs to be adjusted. We
conclude that this treatment protocol is an easily applicable,
safe and highly effective approach for patients with high
grade NHL.
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